Iovance Biotherapeutics Inc (IOVA)
NASDAQ
Fin d'année 31 Décembre 2023 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Return on Assets (%) | -73.754 | -56.264 | -38.85 | -47.865 | -46.641 | -44.282 | -54.935 | -61.487 |
Return on Equity (%) | -75.55 | -58.94 | -40.407 | -51.638 | -54.336 | -53.554 | -70.613 | -81.907 |
Return on Invested Capital (%) | -39.595 | -60.16 | -42.38 | -54.912 | -56.446 | -59.023 | -78.425 | -84.879 |
Operating Margin (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -37638.015 |
Net Profit Margin (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -37345.416 |
Book Value Per Share | 2.681 | 1.988 | 3.777 | 2.296 | 4.358 | 3.889 | 2.621 | 1.373 |
Earnings Per Share | -1.644 | -1.258 | -1.001 | -1.517 | -1.723 | -2.141 | -2.076 | -1.716 |
Cash Per Share | 1.714 | 1.987 | 0.666 | 0.107 | 0.447 | 0.489 | 1.215 | 0.444 |
Working Capital Per Share | 2.643 | 1.905 | 3.735 | 2.131 | 3.858 | 2.62 | 2.033 | 0.763 |
Operating Profit Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -0.037 |
EBIT Per Share | -0.85 | -1.258 | -1.001 | -1.517 | -1.723 | -2.141 | -2.076 | -1.729 |
EBITDA Per Share | -0.85 | -1.258 | -1.001 | -1.517 | -1.723 | -2.141 | -2.076 | -1.729 |
Free Cash Flow Per Share | -1.635 | -1.257 | -0.999 | -1.473 | -1.42 | -1.926 | -2.018 | -1.713 |
Fin d'année 31 Décembre 2023 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Inventory Turnover (Days) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Actions en circulation | 62,25M | 73,16M | 123,42M | 126,41M | 146,88M | 157,01M | 187,81M | N/A |
Fin d'année 31 Décembre 2023 | Sept 2022 | Déc 2022 | Mar 2023 | Juin 2023 | Sept 2023 | Déc 2023 | Mar 2024 | Juin 2024 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Actions en circulation | 157,84M | 187,81M | 224,36M | N/A | N/A | N/A | N/A | N/A |
Return on Assets (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Equity (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Invested Capital (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Operating Margin (%) | N/A | N/A | N/A | N/A | N/A | N/A | -15997.762 | N/A |
Net Profit Margin (%) | N/A | N/A | N/A | N/A | N/A | N/A | -15800.839 | N/A |
Sales Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Earnings Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Cash Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Working Capital Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Operating Profit Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EBIT Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EBITDA Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Free Cash Flow Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Inventory Turnover (Days) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Capitalisation boursière | 1,72B |
Ratio cours/bénéfice | -3,98 |
Ratio prix/ventes | 1,49k |
Ratio prix/liquidités | 15,38 |
Ratio prix/valeur comptable | 3,02 |
Rendement de dividende | - |
Actions en circulation | 304,78M |
Volume moyen (1 semaine) | 7,93M |
Volume moyen (1 mois) | 9,69M |
Variation sur 52 semaines | -24,62% |
Plus haut sur 52 semaines | 18,33 |
Plus bas sur 52 semaines | 5,52 |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales